% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Maass:273938,
      author       = {Maass, Fabian and Canaslan, Sezgi and van Riesen, Christoph
                      and Hermann, Peter and Schmitz, Matthias and Schulte,
                      Claudia and Brockmann, Kathrin and Synofzik, Matthis and
                      Bähr, Mathias and Zerr, Inga},
      title        = {{M}yelin basic protein and {TREM}2 quantification in the
                      {CSF} of patients with {M}ultiple {S}ystem {A}trophy and
                      other {P}arkinsonian conditions.},
      journal      = {Journal of neurology},
      volume       = {272},
      number       = {1},
      issn         = {0367-004X},
      address      = {Heidelberg},
      publisher    = {Springer},
      reportid     = {DZNE-2024-01412},
      pages        = {52},
      year         = {2025},
      abstract     = {It is well known that myelin disruption and
                      neuroinflammation are early and distinct pathological
                      hallmarks in multiple system atrophy (MSA) as well as in
                      idiopathic Parkinson's disease and in other atypical
                      Parkinsonian syndromes. The objective of this study was to
                      assess the value of non-neuronal biomarker candidates that
                      reflect myelin disruption and neuroinflammation.Myelin basic
                      protein (MBP) and the soluble form of TREM2 were quantified
                      in a comprehensive movement disorder cohort from two
                      different neurological centers, comprising a total of 171
                      CSF samples. Commercially available ELISA systems were
                      employed for quantification.The results of the MBP analysis
                      revealed a significant increase in cerebrospinal fluid (CSF)
                      MBP levels in all atypical Parkinsonian conditions compared
                      to PD. This differentiation was more pronounced in the MSA-c
                      subtype compared to MSA-p. Receiver operating characteristic
                      (ROC) analysis revealed a significant discrimination between
                      PD and MSA (p = 0.032, AUC = 0.70), PD and DLB (p = 0.006,
                      AUC = 0.79) and PD and tauopathies (p = 0.006, AUC = 0.74).
                      The results of the TREM2 analysis demonstrated no
                      significant differences between the PD and atypical
                      Parkinsonian groups if not adjusted for confounders. After
                      adjusting for age, sex, and disease duration, the PD group
                      exhibited significantly higher TREM2 levels compared to the
                      DLB group (p = 0.002).In conclusion, MBP, but not TREM2, is
                      elevated in the CSF of not only MSA but in all atypical
                      Parkinsonian conditions compared to idiopathic Parkinson's
                      disease. This highlights the value of the evaluation of
                      myelin/oligodendrocyte-associated markers in
                      neurodegenerative movement disorders.},
      keywords     = {Humans / Multiple System Atrophy: cerebrospinal fluid /
                      Multiple System Atrophy: diagnosis / Female / Male / Aged /
                      Membrane Glycoproteins: cerebrospinal fluid / Middle Aged /
                      Receptors, Immunologic / Biomarkers: cerebrospinal fluid /
                      Myelin Basic Protein: cerebrospinal fluid / Parkinsonian
                      Disorders: cerebrospinal fluid / Parkinsonian Disorders:
                      diagnosis / Parkinson Disease: cerebrospinal fluid /
                      Parkinson Disease: diagnosis / Cohort Studies / Aged, 80 and
                      over / Biomarker (Other) / Cerebrospinal fluid (Other) /
                      Multiple system atrophy (Other) / Myelin basic protein
                      (Other) / TREM2 (Other) / TREM2 protein, human (NLM
                      Chemicals) / Membrane Glycoproteins (NLM Chemicals) /
                      Receptors, Immunologic (NLM Chemicals) / Biomarkers (NLM
                      Chemicals) / Myelin Basic Protein (NLM Chemicals) / MBP
                      protein, human (NLM Chemicals)},
      cin          = {AG Zerr / Clinical Dementia Research (Göttingen) / AG
                      Gasser / AG Fischer},
      ddc          = {610},
      cid          = {I:(DE-2719)1440011-1 / I:(DE-2719)1440015 /
                      I:(DE-2719)1210000 / I:(DE-2719)1410002},
      pnm          = {353 - Clinical and Health Care Research (POF4-353) / 352 -
                      Disease Mechanisms (POF4-352)},
      pid          = {G:(DE-HGF)POF4-353 / G:(DE-HGF)POF4-352},
      typ          = {PUB:(DE-HGF)16},
      pmc          = {pmc:PMC11638341},
      pubmed       = {pmid:39666067},
      doi          = {10.1007/s00415-024-12747-w},
      url          = {https://pub.dzne.de/record/273938},
}